Human Genome Sciences Stock
Equities
US4449031081
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2012 | Actelion Ltd : Exclusive: Human Genome rejected Amgen's $7 billion bid in 2010: sources | RE |
2012 | BioMarin Pharmaceutical Inc. : GSK clinches deal to buy Human Genome for $3 billion | RE |
1st Jan change | Capi. | |
---|---|---|
+4.30% | 43.43B | |
+48.04% | 41.69B | |
+10.25% | 41.31B | |
-10.82% | 27.14B | |
+9.42% | 25.28B | |
-24.44% | 18.47B | |
+34.65% | 12.59B | |
+1.81% | 12.33B | |
+8.88% | 11.03B |
- Stock Market
- Equities
- Stock